59 related articles for article (PubMed ID: 38431746)
1. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
2. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
3. Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Sci Rep; 2024 Mar; 14(1):5153. PubMed ID: 38431746
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
6. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
7. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Int J Clin Oncol; 2023 Sep; 28(9):1183-1190. PubMed ID: 37322220
[TBL] [Abstract][Full Text] [Related]
8. Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Support Care Cancer; 2022 Dec; 30(12):10203-10211. PubMed ID: 36217043
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.
Ikesue H; Yamaoka K; Matsumoto A; Hirabatake M; Muroi N; Yamasaki T; Kawakita M; Hashida T
Cancer Chemother Pharmacol; 2022 Jun; 89(6):833-838. PubMed ID: 35254504
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro.
Nihei S; Asaka J; Takahashi H; Kudo K
Int J Nephrol; 2021; 2021():8381115. PubMed ID: 34912580
[TBL] [Abstract][Full Text] [Related]
12. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kobayashi K; Sugiyama E; Shinozaki E; Wakatsuki T; Tajima M; Kidokoro H; Aoyama T; Nakano Y; Kawakami K; Hashimoto K; Suenaga M; Ichimura T; Ogura M; Chin K; Nakayama I; Ooki A; Takahari D; Suzuki W; Yokokawa T; Minowa Y; Hiraoka T; Suzuki K; Sato H; Hama T; Yamaguchi K
Cancer Chemother Pharmacol; 2021 Jun; 87(6):767-777. PubMed ID: 33635392
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Proteinuria Using Urine Protein : Creatine Ratio in Treatment with Molecular Targeted Agents for Advanced Renal Cell Carcinoma.
Nakamura K; Tanaka T; Masumori N; Miyamoto A; Hirano T
Biol Pharm Bull; 2020; 43(10):1506-1510. PubMed ID: 32999160
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
